References
- Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol.29, 630–634 (1997).
- Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med.341, 142–147 (1999).
- Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol.83, 897–902 (1999).
- Ling LH, Enriquez-Sarano M, Seward JB et al. Clinical outcome of mitral regurgitation due to flail leaflet. N. Engl. J. Med.335, 1417–1423 (1996).
- Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol.48, E1–E148 (2006).
- Goland S, Trento A, Iida K et al. Assessment of aortic stenosis by three-dimensional echocardiography: an accurate and novel approach. Heart93, 801–807 (2007).
- Gutierrez-Chico JL, Zamorano JL, Prieto-Moriche E et al. Real-time three-dimensional echocardiography in aortic stenosis: a novel, simple, and reliable method to improve accuracy in area calculation. Eur. Heart J.29, 1296–1306 (2008).
- Weidemann F, Niemann M, Herrmann S et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur. Heart J.28, 3020–3026 (2007).
- Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol.51, 1369–1374 (2008).
- Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation111, 920–925 (2005).
- Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am. J. Cardiol.59, 998–999 (1987).
- O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol.16, 523–532 (1996).
- Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol.19, 1218–1222 (1999).
- Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aortic-valve disease. N. Engl. J. Med.349, 717–718 (2003).
- O’Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation92, 2163–2168 (1995).
- Galante A, Pietroiusti A, Vellini M et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J. Am. Coll. Cardiol.38, 1078–1082 (2001).
- Liebe V, Kadeni JJ, Isaaci S et al. Coagulation activation is associated with interleukin-6 plasma levels in patients with mechanical prosthetic heart valves. In Vivo20, 427–430 (2006).
- Rajamannan NM, Nealis TB, Subramaniam M et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation111, 3296–3301 (2005).
- Sanchez PL, Santos JL, Kaski JC et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am. J. Cardiol.97, 90–93 (2006).
- Agmon Y, Khandheria BK, Jamil Tajik A et al. Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population. Atherosclerosis174, 337–342 (2004).
- Hsu SY, Hung KC, Chang SH, Wen MS, Hsieh IC. C-reactive protein in predicting coronary artery disease in subjects with aortic valve sclerosis before diagnostic coronary angiography. Am. J. Med. Sci.331, 264–269 (2006).
- O’Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation106, 2224–2230 (2002).
- Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum. Pathol.34, 756–763 (2003).
- Chalajour F, Treede H, Ebrahimnejad A, Lauke H, Reichenspurner H, Ergun S. Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp. Cell Res.298, 455–464 (2004).
- Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation103, 1522–1528 (2001).
- Rajamannan NM, Subramaniam M, Rickard D et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation107, 2181–2184 (2003).
- Rajamannan NM, Subramaniam M, Springett M et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation105, 2660–2665 (2002).
- Caira FC, Stock SR, Gleason TG et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol.47, 1707–1712 (2006).
- Andropova OV, Polubentseva EI, Anokhin VN. [Factors facilitating development of degenerative aortic valvular stenosis]. Klin. Med. (Mosk.)83, 51–54 (2005).
- Gunduz H, Akdemir R, Binak E, Tamer A, Keser N, Uyan C. Can serum lipid and CRP levels predict the “severity” of aortic valve stenosis? Acta Cardiol.58, 321–326 (2003).
- Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev. Endocr. Metab. Disord.7, 41–49 (2006).
- Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation112, 1229–I234 (2005).
- Fukuda N, Shinohara H, Sakabe K, Nada T, Tamura Y. Plasma levels of brain natriuretic peptide in various forms of obstruction to the left ventricular outflow tract. J. Heart Valve Dis.12, 333–340 (2003).
- Qi W, Mathisen P, Kjekshus J et al. Natriuretic peptides in patients with aortic stenosis. Am. Heart J.142, 725–732 (2001).
- Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur. J. Heart Fail.3, 15–19 (2001).
- Weber M, Arnold R, Rau M et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am. J. Cardiol.94, 740–745 (2004).
- Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation107, 1884–1890 (2003).
- Prasad N, Bridges AB, Lang CC et al. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am. Heart J.133, 477–479 (1997).
- Vanderheyden M, Goethals M, Verstreken S et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J. Am. Coll. Cardiol.44, 2349–2354 (2004).
- Ikeda T, Matsuda K, Itoh H et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am. Heart J.133, 307–314 (1997).
- Qi W, Mathisen P, Kjekshus J et al. The effect of aortic valve replacement on N-terminal natriuretic propeptides in patients with aortic stenosis. Clin. Cardiol.25, 174–180 (2002).
- Lim P, Monin JL, Monchi M et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur. Heart J.25, 2048–2053 (2004).
- Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation109, 2302–2308 (2004).
- Moura LM, Zamorano J, Ramos S, Azevedo LF, Rocha-Goncalves F, Rajamannan N. Rosuvastatin Affecting Aortic Valve Endothelium (RAAVE) to slow the progression of aortic stenosis. Circulation Suppl. II, 112–117 (2005).
- Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol.49, 554–561 (2007).
- Moura LM. Doctoral Thesis. Statin’s effects on valvular aortic stenosis. Madrid: Universidad Complutense de Madrid (2007).
- Gerber IL, Legget ME, West TM, Richards AM, Stewart RA. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am. J. Cardiol.95, 898–901 (2005).
- Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am. Heart J.148, 895–902 (2004).
- Laukkanen JA, Kurl S, Eranen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. Arch. Intern. Med.165, 1788–1793 (2005).
- Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am. J. Cardiol.90, 1284–1289 (2002).
- Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J.28, 230–268 (2007).
- Kerr AJ, Raffel OC, Whalley GA, Zeng I, Stewart RA. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. Eur. Heart J.29, 363–370 (2008).
- Baumgartner H. Neurohormones in valvular heart disease: what can they tell us? Eur. Heart J.29, 290–292 (2008).
- Faggiano P, Antonini-Canterin F, Erlicher A et al. Progression of aortic valve sclerosis to aortic stenosis. Am. J. Cardiol.91, 99–101 (2003).
- Pohle K, Maffert R, Ropers D et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation104, 1927–1932 (2001).
- Libby P. Inflammation in atherosclerosis. Nature420, 868–874 (2002).
- Pasowicz M, Konieczynska M, Podolec P et al. Evaluation of the relationship between selected markers of the inflammatory process and aortic valve calcifications. Acta Cardiol.59, 219–221 (2004).
- Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation111, 3316–3326 (2005).
- Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol.23, 1162–1170 (1994).
- Kaden JJ, Dempfle CE, Grobholz R et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc. Pathol.14, 80–87 (2005).
- Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart88, 348–351 (2002).
- Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation107, 391–397 (2003).
- Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ. Res.89, 763–771 (2001).
- Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med.252, 283–294 (2002).
- Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107, 499–511 (2003).
- Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, 836–843 (2000).
- Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation101, 1767–1772 (2000).
- Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation101, 2149–2153 (2000).
- Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation106, 820–825 (2002).
- Ridker PM, Shih J, Cook TJ et al. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation105, 1776–1779 (2002).
- Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation103, 491–495 (2001).
- Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation104, 2266–2268 (2001).
- Brown DA, Breit SN, Buring J et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case–control study. Lancet359, 2159–2163 (2002).
- Rajamannan NM, Subramaniam M, Stock SR et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart91, 806–810 (2005).
- Gerber IL, Stewart RA, Hammett CJ et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am. J. Cardiol.92, 1129–1132 (2003).
- Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol.48, 598–675 (2006).
- Jeevanantham V, Singh N, Izuora K, D’Souza JP, Hsi DH. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. Mayo Clin. Proc.82, 171–174 (2007).
- Balk EM, Lau J, Goudas LC et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med.139, 670–682 (2003).
- Moura LM, Zamorano J, Mataix L et al. Effects of statins on soluble CD40 ligand, high sensitive C-reactive protein and interlueukin-6 levels in patients with aortic stenosis: establishing a cause-effect relationship. Eur. Heart J.26, 384 (2005).
- Pearson TA, Mensah GA, Hong Y, Smith SC Jr. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to clinical and public health practice: overview. Circulation110, E543–E544 (2004).
- Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med.352, 20–28 (2005).
- Rajamannan NM. Is it time for medical therapy for aortic valve disease? Exp. Rev. Cardiovasc. Ther.2(6), 845–854 (2004).
- Morrow DA (Ed.). Cardiovascular Biomarkers. Humana Press, NJ, USA (2006)